BBIO News and Press, BridgeBio Pharma Inc. From 10/06/23

2023-10-06 18:09:48 ET Summary The biotechnology and pharmaceutical sectors have been under pressure in 2023, with the Invesco Pharmaceuticals ETF down 9% and the iShares Biotechnology ETF down 6%. Elevated interest rates and potential pricing power erosion are the primary headwin...

Resilience to manufacture BridgeBio’s lead investigational gene therapy treatments, BBP-631 and BBP-812 Partnership provides an innovative, capital efficient, sustainable model for BridgeBio to develop, test and deliver transformative medicines for patients more quickly PAL...

2023-09-28 11:07:29 ET More on BioMarin Pharmaceutical BioMarin: Q2 2023 Confirmed My Bullish View BioMarin: More Growth Is Coming BioMarin upgraded at BMO after FDA nod for hemophilia A therapy Seeking Alpha’s Quant Rating on BioMarin Pharmaceutical ...

2023-09-25 23:05:32 ET Summary BridgeBio Pharma's Q2 2023 YoY revenue plummeted, but PIPE financing extends cash runway to 15 months, alleviating short-term liquidity concerns. Acoramidis poses a threat to Pfizer's tafamidis in ATTR-CM space, pending FDA approval; yet high debt an...

2023-09-25 07:45:19 ET More on BridgeBio Pharma Seeking Alpha’s Quant Rating on BridgeBio Pharma Historical earnings data for BridgeBio Pharma Financial information for BridgeBio Pharma BridgeBio: Positive Updated Acoramidis Data May Not Imply Further ...

- $250 million financing led by Qatar Investment Authority (QIA) with significant participation from four of the largest investment management firms in the US - BridgeBio anticipates this raise, coupled with several less dilutive financings available to the Company, fully capitalizes th...

2023-09-13 08:08:13 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips The pharmaceutical industry is one of the most dynamic and innovative sectors in the world. It is constantly developing new drugs and treatments to address various health challenges and improve...

2023-09-11 07:19:20 ET Summary This article provides a follow-up study reviewing the 6-month performance of the top "zombie" firm portfolio selections based on Federal Reserve metrics. Three different model returns from March are reviewed, with sample stock portfolios down -23.4%,...

PALO ALTO, Calif., Sept. 07, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that members of its management team will pr...

- BridgeBio completed an end-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA), and a scientific advice engagement with the European Union (EU) European Medicines Agency (EMA) - FDA and EMA alignment was reached on the adequacy of a one-year, 2:1 randomized, placebo-co...